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S U M M A R Y
The purpose of this study was to investigate the penetration of linezolid into the mediastinum and pleural
space by comparing its concentration in the serum, mediastinum, and pleural space. The linezolid area
under the concentration-versus-time curve from zero to 12 h (AUC)mediastinum ﬂuid/serum and AUCpleural
ﬂuid/serum ratio were 1.32 and 1.64, respectively. The results suggest that the linezolid concentration in the
mediastinum varies as in the serum, and that the concentration in the mediastinum is the same as or
greater than that in the serum.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Mediastinitis following cardiovascular surgery remains an
intractable complication associated with considerable mortality.
Mediastinitis due to methicillin-resistant Staphylococcus aureus
(MRSA) has been reported and is associated with higher rates of
overall mortality.1 Linezolid is a synthetic oxazolidinone antimi-
crobial agent that has good activity against most medically
important Gram-positive microorganisms resistant to methicillin
and vancomycin. Although a number of studies have shown
linezolid to be effective against MRSA mediastinitis in vitro, only
limited results on their efﬁcacy and pharmacokinetics in animal
models have been reported.2 To date, no clinical trials evaluating
the best antimicrobial regimen for treating MRSA mediastinitis
infections have been published.
The purpose of the present study was to examine the
penetration of linezolid into the mediastinum and pleural space
by comparing their linezolid concentrations with that of the serum
of peripheral blood. Here, we describe two cardiovascular surgery* Corresponding author. Tel.: +81 76 415 8815; fax: +81 76 434 7584.
E-mail address: ytsuji@pha.u-toyama.ac.jp (Y. Tsuji).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.03.008patients who were treated with linezolid and demonstrate that the
concentration of linezolid in the mediastinum was higher than that
in the serum.
2. Methods
The subjects in this study were two Japanese elderly male
patients who had undergone coronary artery bypass graft (CABG)
surgery at Sasebo Chuo Hospital. These surgeries were performed
using median sternotomy. Two drainage chest tubes were placed
in the mediastinum and pleural space. Linezolid was used to
prevent an MRSA infection in the ﬁrst patient (case 1). Linezolid
(600 mg/dosage) was administered by continuous intravenous
drip infusion for 60 to 120 min at 12-h intervals. The second
patient (case 2) developed MRSA mediastinitis after CABG. This
patient was administered vancomycin, but no improvement was
observed. Thereafter, linezolid was administered, which resulted
in the resolution of the infection.
Blood samples were collected immediately before administra-
tion (C1), 2 h after administration (C2), and 12 h immediately
before administration (C3). Mediastinum and pleural effusions
from the indwelling drainage chest tubes were sampled. Linezolid
concentrations in the serum and in the mediastinum and pleuralses. Published by Elsevier Ltd. All rights reserved.
Table 1
Linezolid concentrations in the serum, and mediastinum and pleural effusions of patients with MRSA mediastinitis
Case 1 Case 2
C1 C2 C3 C1 C2 C3
Serum Concentration (mg/ml) 10.2 - - 22.0 - -
AUC0–12 (mgh/ml) 236.4 (mean) 272.7 200.0
Mediastinum ﬂuid Concentration (mg/ml) - 9.9 12.8 24.3 23.5 -
AUC0–12 (mgh/ml) 312.5 (mean) 375.0 250.0
AUC mediastinum/serum ratio 1.32
Pleural ﬂuid Concentration (mg/ml) - 11.3 16.6 - 29.0 -
AUC0–12 (mgh/ml) 388.7 (mean) 461.5 315.8
AUC pleural/serum ratio 1.64
Total and free linezolid concentrations were determined using high-performance liquid chromatography. The concentrations of linezolid immediately before administration
(C1), 2 h after administration (C2), and 12 h immediately before administration (C3) are shown. AUC is the linezolid area under the concentration-versus-time curve from zero
to 12 h.
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raphy (HPLC). The minimum inhibitory concentration (MIC) of
isolated MRSA was determined by the agar dilution method using
the Clinical and Laboratory Standards Institute guidelines.
Linezolid pharmacokinetics were estimated using NONMEM1
software version 7.2.0 (ICON Development Solutions, Ellicott City,
MD, USA); for the convergence of the Bayesian nonlinear least-
squares method, the 1-compartment model was applied to the
analysis of linezolid concentrations. Based on the concentration of
linezolid just before the third administration (C1) in case 1 and just
before the thirteenth administration (C1) in case 2, we simulated a
serum concentration transition proﬁle.
3. Results
The linezolid area under the concentration-versus-time curve
from zero to 12 h in serum (AUC serum), the mediastinum ﬂuid
(AUC mediastinum ﬂuid), and the pleural ﬂuid (AUC pleural ﬂuid),
and various pharmacokinetic parameters, are presented in Table 1.
AUC serum was 236.4 mgh/ml (mean), AUC mediastinum ﬂuid
was 312.5 mgh/ml (mean), and AUC pleural ﬂuid was 388.7 mgh/
ml (mean), with an AUCmediastinum ﬂuid/serum ratio of 1.32 and
AUCpleural ﬂuid/serum ratio of 1.64. The linezolid minimum inhibitory
concentrations for 90% (MIC90) of MRSA isolated from two male
patients were <2 mg/ml.
4. Discussion
Mediastinitis is a relatively uncommon infection involving
structures in the mediastinum and may result from a variety of
underlying etiologies, including esophageal perforation, extension
from head and neck infections, pneumonia, infected lymph nodes,
or an infected sternotomy site. The antibiotics traditionally used
for the treatment of MRSA mediastinitis, such as vancomycin, are
limited, and new therapeutic approaches are required. Antibiotic
agent penetration (such as that of vancomycin) into the
mediastinum space is low because the mediastinum space is
separated from the bloodstream. The transfer of linezolid to tissue
has been shown to be superior to that of vancomycin.2 Gee et al.
reported that linezolid had good tissue penetration, with its
penetration into inﬂammatory ﬂuid being 104%.3 Therefore, it may
be used as an effective treatment for mediastinitis. However, little
is known about the penetration of linezolid into the mediastinum
and pleural space.The present study indicates that the concentration of linezolid
in the mediastinum and pleural space is a concentration transition
that is higher than serum. Linezolid has a wide spectrum of
antibacterial activity against Gram-positive bacteria with a MIC90
of 4 mg/ml, such as MRSA.4 Andes et al. reported that a linezolid
regimen of 600 mg given twice daily to humans was effective
against organisms with MICs of up to 2–4 mg/ml, based on a
pharmacodynamic goal of achieving a 24-h AUC/MIC ratio of
50–100.5 We suggested that the serum concentration transition of
linezolid in our patients should exceed the MIC and achieve the
aimed for AUC/MIC. The results of the present study show that the
AUC of the mediastinum and pleural space were higher than that of
the serum.
In conclusion, linezolid transferred easily from blood to the
mediastinum and pleural tissue in these patients. The ﬁndings of
this study suggest that the use of linezolid for the treatment
of MRSA mediastinitis is enabled by the tissue penetration of
linezolid. As the frequency of secondary infections by drug-
resistant organisms such as Staphylococcus aureus continues to rise,
more studies on drugs used for mediastinum infections, such as
linezolid, are necessary for the development of effective treatment
regimens for MRSA mediastinitis.
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